National Contact Point LIFESCIHEALTH Dr. Wilfried Diekmann Königswinterer Str. 522-524, 53227 Bonn

Nationale Kontaktstelle

Lebenswissenschaften

National Contact Point LIFESCIHEALTH

Dr. Wilfried Diekmann

Königswinterer Str. 522-524, 53227 Bonn

phone: +49 228 447 698, e-mail: [email protected]

http://www.nks-lebenswissenschaften.de

ERA-NET PathoGenoMics

2nd NSC & 3rd EB Meeting, April 07, 2005

Strategic supporting measures

to raise synergies with the European framework programmes and

to embed PathoGenoMics into the European R&D Landscape



a) Fundamental knowledge & basic tools for functional genomics in all organisms

Geneexpression

andproteomics

Structuralgenomics

Comparative genomics

andpopulationgenetics

Bio-informatics

Multidisciplinary functional genomics approaches to basic biological processes

i) Advanced Genomics and its applications for health

b) Application of knowledge and technologies in the field of genomics and biotechnology for health

New,safer,more

effective drugs(incl. pharmaco-

genomics)

Newdiagnostics

New in vitrotests to

replace animalexperimentation

New preventive and therapeutic tools

(somatic gene and celltherapies; stem cell and immunotherapies, etc.)

Innovative research in post-genomics with

high potential forapplication

ii) Combating major diseases

b) Cancer c) Poverty-related diseases

• HIV / AIDS• Malaria• Tuberculosis

Cardiovascular disease,diabetesand rarediseases

Resis-tance to

antibioticsand other

drugs

Brain anddiseases ofthe nervous

system

Human development

andthe ageing

process

a) Application-orientated genomic approaches

TP 1 Life Science, Genomics and Biotechnology for HealthProgramme structure and pathogenomics-relevant areas



3rd Call (FP-2004-LIFESCIHEALTH-5, deadline: 16.11.2004)Selected pathogenomics-relevant areas

Activity Code Areas addressed Instr.

LIFESCIHEALTH-1.1 Fundamental genomics

LSH-2004-1.1.0-1/2/3 Topics for STREP/CA/SSA across the Fundamental genomics area in all organisms SSA, CA, STREP

LIFESCIHEALTH-1.2 Applied genomics LIFESCIHEALTH-1.2.5 Innovative research in post-genomics

LSH-2004-1.2.5-4 Post genomic approaches for tackling complex multifactorial diseases (except Cancer) STREP

LIFESCIHEALTH-2 Combating major diseases

LIFESCIHEALTH-2.1.2 Combating resistance to antibiotics and other drugs

LSH-2004-2.1.2-1 Management of lower respiratory tract infections NoELSH-2004-2.1.2-2 The role of mobile genetic elements in the generation of antimicrobial resistance STREP

LSH-2004-2.1.2-3Improved understanding of ecological factors with impact on the genetic and molecular determinants of fitness and virulence of resistant bacterial pathogens

STREP

LSH-2004-2.1.2-4 Control of anti-fungal drug resistance (especially orientated towards SMEs) STREP

LSH-2004-2.1.2-5Workshop on translation of research results on antimicrobial resistance into clinical practice

SSA

LSH-2004-2.1.2-6 Workshop for set up of a centrally supported system for annotation of microbial genomics SSA

LIFESCIHEALTH-2.2 Combating cancer

LSH-2004-2.2.0-3 Research on tumours associated with infectious agents IP

LIFESCIHEALTH-2.3 Confronting the major communicable diseases linked to poverty

LSH-2004-2.3.0-4 Development of new drugs for the treatment of tuberculosis IPLSH-2004-2.3.0-7 Research in poverty-related diseases (PRD) by SMEs STREPLSH-2004-2.3.0-9 Coordination of PRD activities between biotech industry, bioincubators & biotech investors CA



FP6 project portfolio in pathogenomicsPathogenomics-relevant proposals to the 3rd Call

Area IP NoE STREP CA SSA

1.1 Fundamental Genomics proposed 2 8 2

selected 1 1

1.2 Biotech & Applied Genomics proposed 1 2

ranked* 0 0

2.1 Major Diseases proposed 1 16 1

ranked 1 8 0

2.2 Major Diseases (Cancer) proposed 4

ranked*

2.3 Poverty-related diseases proposed 4 6

ranked* 2 2

3. Specific support actions proposed 1

ranked* 0

2

10

* based on panel priority lists, i.e. major priority lists of COM services are not yet available



FP6 project portfolio in pathogenomicsTP LSH, Fundamental Genomics, Outcome 3rd Call

STREP

Non-coding RNAs in bacterial pathogenicity (BACRNAs)Major Priority List; Coordinator: University of Vienna, AT

CA

Strategy to build up and maintain an integrated sustainable European fungal genomic database required for innovative genomics research on filamentous fungi important for biotechnology and human health (EUROFUNGBASE)Major Priority List; Coordinator: Universiteit Leiden, NL



FP6 project portfolio in pathogenomicsTP LSH, Major Diseases, Outcome 3rd Call

NoEGenomics to Combat Resistance against Antibiotics in Community-acquired Lower Respiratory Tract Infections in Europe (GRACE)NI Panel Priority Order 10; Coordinator: Universiteit Antwerpen; BE

STREPsCombating resistance to antibiotics (CORANIX)TI Panel Priority Order 7; Coordinator: Institut Pasteur, FR

Effects of antibiotic resistance on bacterial fitness, virulence and transmission(EAR)TI Panel Priority Order 9; Coordinator: Uppsala University, SE

Role of Mobile Genetic Elements in the Spread of Antimicrobial DrugResistance (DRESP2)TI Panel Priority Order 10; Coordinator: Universita degli Studi di Siena, IT

Functional genomic characterisation of molecular determinants forstaphylococcal fitness, virulence and drug resistance (StaphDynamics)TI Panel Priority Order 16; Coordinator: University of Groningen, NL

Major Priority ?

Reserve List ?



FP6 project portfolio in pathogenomicsTP LSH, Major Diseases, Outcome 3rd Call

Further STREPs passed the threshold:

Antifungal drug resistance in the human pathogen Candida glabrata (ANTIGLA)TI Panel Priority Order 18; Coordinator: Instituto Superior Técnico, PT

Combating Candida drug resistance, CDR, by novel drugs especially actingthrough interference with CDR regulatory network (CombatingCDR)TI Panel Priority Order 19; Coordinator: Universität Bonn, DE

Factors affecting transfer and mobilization of extended spectrum beta-lactamases (MOBILACT)TI Panel Priority Order 21; Coordinator: University of Warwick, UK

ADaptation of VANComycin-resistant Enterococci and Staphylococci:Ecological determinants of fitness and virulence(ADVANCES)TI Panel Priority Order 22; Coordinator: University Medical Centre Utrecht, NL

Control of Resistance in Invasive Fungal Infection and Diagnosis (CRIFID)TI Panel Priority Order 23; Coordinator: University Medical Centre Nijmegen, NL

Role of Genetic and Molecular Determinants in Survival and Spread ofFoodborne Antibiotic Resistant Bacteria (FoodRBug)TI Panel Priority Order 25; Coordinator: University of Birmingham, UK



FP6 project portfolio in pathogenomicsTP LSH, Major Diseases (Cancer), Outcome 3rd Call

IPs

The role of chronic INfections in the development of CAncer (INCA)NI Panel Priority Order 3; Coordinator: Medizinische Hochschule Hannover, DE

Linking Cancer Transcriptome to Proteome: Functional Oncogenomics forDiagnosis and Treatment of Human Cancers related to Infectious Agents(EUROVIRC)NI Panel Priority Order 12; Coordinator: Fondazione Andrea Cesalpino, IT



FP6 project portfolio in pathogenomicsTP LSH, Poverty-related diseases (i.e. tuberculosis),

Outcome 3rd CallIPs

New medicines for tuberculosis (NM4TB)NI Panel Priority Order 1; Coordinator: Institut Pasteur, FR

A Consortium for Tuberculosis Drug Development (TB-DD)NI Panel Priority Order 7; Coordinator: University of Zürich, CH

STREPs

Innate and adaptive immunity in clinical and experimental mycobacterial infection in neonates and infants (NEOTIM)TI Panel Priority Order 5; Coordinator: Karolinska Institutet, SE

New drugs for persistent tuberculosis: Exploitation of 3-D structure of novel targets, lead optimisation and functional in vivo evaluation (NewTBDrugs)TI Panel Priority Order 6; Coord.: LIONEX Diagnostics & Therapeutics GmbH, DE



Framework Programme 6, LIFESCIHEALTHFundamental Genomics, Topics for 4th Call

Gene expression and proteomics • A systems approach to understanding the regulation of gene transcription – IP

Structural genomics • Structural genomics interdisciplinary initiative – IP

Comparative genomics and population genetics• Functional genomics in Arabidopsis thaliana - IP • High throughput phenotyping tools and approaches for large scale functional genomics studies – IP • Population cohorts for molecular epidemiological studies in European populations – IP

Multidisciplinary functional genomics approaches to basic biological processes • Functional genomics of autosomal aneuploid syndromes - IP• The biological role of small regulatory RNAs - IP

• Specific Support Actions (SSAs)

• Co-ordination Actions (CA)

• Tools and technologies for functional genomics – STREP dedicated to SMEs



Framework Programme 6, LIFESCIHEALTHBiotech & Applied Genomics, Topics for 4th Call

New, safer, more effective drugs including pharmacogenomics • Marker profiling as a new tool for predictive toxicology - IP• New tools to investigate ADME properties of drugs involving a carrier system – STREP

New diagnostics• High throughput molecular diagnostics for hereditary diseases - IP • Development of innovative methods for diagnosis of nervous system disorders – STREP• Nanoparticles-based diagnostics – STREP

New in vitro tests to replace animal experimentation• Predictive in vitro testing strategies for human exposure to chemicals - IP• Workshop on business opportunities for in vitro pharmaceutical toxicology – SSA • Researchers and regulators meet manufacturers of toxicology test methods – SSA

New preventive & therapeutic tools, somatic gene and cell therapies, stem cells, immunotherapies• Tissue engineering approaches to treating children with birth defects - IP • Hepatitis C vaccine - IP • Stem Cell Therapy for Stroke Patients – STREP• Methodological research to underpin stem cell banking - STREP• Use of baculovirus as a vector in gene therapy – STREP towards SME

Innovative research in post-genomics, which has high potential for application• Application of post-genomics to xenotransplantation research – IP• Approaches exploiting aquatic molecular biodiversity for biomedical applications - IP • Use of cell lines to define new bioassays for the identification of therapeutic biomolecules – STREP to SME

• All areas – STREP dedicated to SMEs



Framework Programme 6, LIFESCIHEALTHMajor Diseases, Topics for 4th Call

A) APPLICATIONS-ORIENTATED GENOMIC APPROACHES

General (overarching)• Genetic control of the pathogenesis of diseases based on iron metabolism – STREP

Combating, cardiovascular disease, diabetes and rare diseases• Genomic-wide mapping and functional genomics of susceptibility to coronary artery disease – IP • Hypertension and cardiovascular disease – NOE • Prevention of accelerated cardiovascular death in uraemia and end-stage renal disease - STREP • Functional genomics and regulatory networks in lipid metabolism & their effects on atherogenic

vascular disease development - STREP • Gene-environment interaction on the incidence of type 2 diabetes - IP • Molecular pathways underlying decreased beta cell mass in diabetes mellitus – STREP• Rare inherited neuromuscular disorders: from molecular basis to cutting edge therapies - NOE• Rare disorders of protein folding – STREP • Rare diseases of connective tissues affecting bone and/or cartilage – STREP• Research on cardiovascular and/or cerebrovascular disease – STREP towards SME• Preventive and therapeutic strategies for Type 1 diabetes – STREP towards SME• Development of in vitro and/or animal models for rare diseases – STREP towards SME



Framework Programme 6, LIFESCIHEALTHMajor Diseases, Topics for 4th Call

Combating resistance to antibiotics and other drugs• Control of antimicrobial resistance in hospital acquired and health care associated infections – IP

• Molecular ecology of antibiotic drug resistance – IP • Workshop exploring novel opportunities towards vaccines and control of anti-bacterial resistance - SSA• New diagnostic tests for the management & control of antimicrobial resistance – STREP towards SME• Novel principles for anti-microbial treatment – STREP towards SME

Studying the brain and combating diseases of the nervous system• Functional genomics and neurobiology of epilepsy – IP• Neuroimaging: “Bridging genetics and neural function” – IP• Cortical information processing – STREP • Schizophrenia: from genotype to phenotype – STREP • Initiative in neuroinformatics – SSA • Neuroscience-oriented new technologies – STREP towards SME • Animal models for neurological and psychiatric diseases – STREP towards SME • Early markers and new targets for neurodegenerative diseases – STREP towards SME• Perinatal brain damage: early markers and neuroprotection – STREP towards SME

Studying human development and the ageing process• Integration of research in development and ageing - NOE• Attracting researchers to ageing research - SSA• Responsiveness of elderly people towards vaccination and infectious diseases – STREP towards SME



Framework Programme 6, LIFESCIHEALTHMajor Diseases (Cancer), Topics for 4th Call

COMBATING CANCER• Modulation of apoptosis in cancer prevention and therapy – IP

• Broadening the knowledge base on the molecular mechanisms underlying chemotherapy resistance, therapeutic escape, efficacy and toxicity – IP

• Early diagnosis and novel therapies of solid childhood cancers – STREP

• Innovative research on palliative care in patients with advanced stages of cancer – STREP

• Role of chromosomal aberrations and epigenetic mechanisms of leukaemia – STREP

• Identification and validation of biomarkers in molecular cancer epidemiology – STREP

• Exploring the patient’s cancer stem cell as a novel therapeutic target – STREP

• Conference on cell differentiation, plasticity and cancer – SSA

• Innovative technological approaches for cancer therapy – STREP towards SMEs

• Small-ligand libraries: improved tools for exploration and prospective anti-tumor therapy - STREP towards SMEs

• Improving resolution of current imaging devices relevant to cancer diagnosis and therapy - STREP towards SMEs

• Application of “molecular signatures” for the early diagnosis of cancer patients - STREP towards SMEs



Framework Programme 6, LIFESCIHEALTHPoverty-related diseases (PRD), Topics for 4th Call

CONFRONTING THE MAJOR COMMUNICABLE DISEASES LINKED TO POVERTY

• HIV/AIDS Therapeutic Clinical trials network - NOE

• HIV/AIDS Vaccines/Microbicides Network - NOE

• Rationale Design of Malaria Vaccine - IP

• New approaches for research into host/vector-pathogen interaction for HIV/AIDS, malaria and tuberculosis – STREP

• Undesirable consequences of drugs and vaccines for Poverty-related Diseases – STREP

• Integration & coordination of European clinical research on PRD - SSA/CA

• Promotion of PRD research - SSA/CA

• European Network for vaccine development covering the three diseases - SSA/CA

• Improving participation of the private sector in PRD research – SSA towards SME

• SME-driven innovations for poverty related diseases – STREP towards SME

• Development of fast tests for diagnosis of poverty related diseases suitable for use in resource-poor settings – STREP towards SME

• Innovative delivery mechanism for treatment and depot therapy in Poverty-related diseases – STREP towards SME



Framework Programme 6, LIFESCIHEALTHSpecific Support Actions across TP1; Topics for 4th Call

• Promoting Collaboration between SMEs and Academia

• Stimulating international co-operation

• Promotion of cooperation with Associated Candidate Countries (ACC)

• Realising ERA objectives

• Life sciences and biotechnology – A strategy for Europe.

• Supporting policy development

• Scientific and project management

• Mapping and identifying research efforts and contributions from FPs in the context of the European Community’s Public Health Programme, in the fields of health information, health threats and health determinants, with particular regard to mental health, reducing health risks, and preventing major as well as specific diseases.

• Mapping and identifying research efforts and contributions from FPs in the context of the European Environment and Health Action Plan, in the fields of gene-environment interactions, respiratory diseases, neuro-developmental disorders, cardiovascular diseases and cancers, with particular regard to children’s health

• Foresight study in the area of biotechnology and health

• European human embryonic stem cell registry

National Contact Point LIFESCIHEALTH Dr. Wilfried Diekmann Königswinterer Str. 522-524, 53227 Bonn

Documents

Transcript of National Contact Point LIFESCIHEALTH Dr. Wilfried Diekmann Königswinterer Str. 522-524, 53227 Bonn